Market Overview:
The global systemic idiopathic juvenile arthritis treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of juvenile arthritis, rising awareness about available treatments, and growing demand for biosimilars. Based on type, the global systemic idiopathic juvenile arthritis treatment market is segmented into adalimumab biosimilar, canakinumab, golimumab, and tocilizumab biosimilar. The adalimumab biosimilar segment is expected to account for the largest share of the global market in 2018 owing to its high efficacy and safety profile as compared to other types of biologics used for treating juvenile arthritis. Based on application, the global systemic idiopathic juvenile arthritis treatment market is segmented into clinic-based applications and hospital-based applications. The clinic-based applications segment is expected to account for a larger share of the overall market in 2018 due mainly to higher patient awareness about available treatments options and growing demand for early diagnosis and intervention therapies.
Product Definition:
Systemic Idiopathic Juvenile Arthritis Treatment is a medical term used to describe the treatment of juvenile arthritis that affects multiple joints throughout the body. The goal of systemic idiopathic juvenile arthritis treatment is to reduce inflammation, pain, and stiffness and improve mobility. Treatment may include medications such as anti-inflammatory drugs, steroids, or biologics; physical therapy; and/or dietary modifications.
Adalimumab Biosimilar:
Adalimumab is a humanized monoclonal antibody that was developed by recombinant DNA technology. It is used to treat patients who are unresponsive to conventional therapy for rheumatoid arthritis and Crohn's disease. The drug works by binding to the interleukin (IL) - 1 receptor site and neutralizing the harmful effects of cytokines, which cause inflammation in the body.
Canakinumab:
Canakinumab (AKA Canakinumab vedotin) is a fully human monoclonal antibody. Monoclonal antibodies are manufactured by immune cells called B-lymphocytes which are taken from the patient's own body. These antibodies can bind themselves to specific molecules and hence block or slow down the activity of particular genes, proteins or enzymes that cause inflammation.
Application Insights:
Based on application, the global systemic juvenile idiopathic arthritis treatment market is segmented into clinic, hospital and others. Clinic held the largest share of more than 60% in 2017. This large share can be attributed to a high number of patients seeking diagnosis and treatment for various conditions such as joint pain and swelling in children. Moreover, an increase in prevalence rates of Systemic Juvenile Idiopathic Arthritis (SJIA) has resulted in increased demand for diagnostic tests which further drives the overall market growth. For instance, according to statistics published by Arthritis Foundation Inc., around 1 out of every 15 children aged between 6 months to 17 years have been found to have arthritis or lupus compared with only 1 child out of 100 thousand before 1980¢â‚¬â„¢s worldwide incidence rate was 10 per million population annually from 1980-1999; thus increasing incidences across the globe has led towards higher demand globally over recent past years.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of players, high adoption rate for new drugs, and favorable reimbursement policies are some factors contributing to the growth of this regional market. In addition, increasing awareness about SLE and growing healthcare expenditure are expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR over the forecast period owing to rising incidence rates of systemic idiopathic juvenile arthritis coupled with improving economic conditions in emerging countries such as China and India. Moreover, an increase in government initiatives for disease management is also expected favorably impact overall revenue generation over the next eight years.
Growth Factors:
- Increasing incidence of Systemic Idiopathic Juvenile Arthritis Treatment across the globe.
- Rising awareness about Systemic Idiopathic Juvenile Arthritis Treatment among people.
- Technological advancements in the field of diagnosis and treatment of Systemic Idiopathic Juvenile Arthritis Treatment .
- Availability of government funding for research on Systematic Idiopathic Juvenile Arthritis Treatment . 5 Increased number of collaborations and partnerships between key players operating in the market for development and commercialization of new therapies/products
Scope Of The Report
Report Attributes
Report Details
Report Title
Systemic Idiopathic Juvenile Arthritis Treatment Market Research Report
By Type
Adalimumab Biosimilar, Canakinumab, Golimumab, Tocilizumab Biosimilar, Others
By Application
Clinic, Hospital, Others
By Companies
Alteogen Inc., Bristol-Myers Squibb Company, Epirus Biopharmaceuticals, Inc., Johnson & Johnson, Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., Novartis AG, Oncobiologics, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Systemic Idiopathic Juvenile Arthritis Treatment Market Report Segments:
The global Systemic Idiopathic Juvenile Arthritis Treatment market is segmented on the basis of:
Types
Adalimumab Biosimilar, Canakinumab, Golimumab, Tocilizumab Biosimilar, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alteogen Inc.
- Bristol-Myers Squibb Company
- Epirus Biopharmaceuticals, Inc.
- Johnson & Johnson
- Momenta Pharmaceuticals, Inc.
- Mycenax Biotech Inc.
- Novartis AG
- Oncobiologics, Inc.
Highlights of The Systemic Idiopathic Juvenile Arthritis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Adalimumab Biosimilar
- Canakinumab
- Golimumab
- Tocilizumab Biosimilar
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Systemic Idiopathic Juvenile Arthritis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Systemic idiopathic juvenile arthritis (SJIA) is a rare form of arthritis that affects the joints. SJIA is caused by a unknown cause and usually starts between the ages of 10 and 15 years old. SJIA can be very difficult to treat, but there are treatments available that can help improve symptoms.
Some of the major companies in the systemic idiopathic juvenile arthritis treatment market are Alteogen Inc., Bristol-Myers Squibb Company, Epirus Biopharmaceuticals, Inc., Johnson & Johnson, Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., Novartis AG, Oncobiologics, Inc..
The systemic idiopathic juvenile arthritis treatment market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Systemic Idiopathic Juvenile Arthritis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Systemic Idiopathic Juvenile Arthritis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Systemic Idiopathic Juvenile Arthritis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Systemic Idiopathic Juvenile Arthritis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size & Forecast, 2020-2028
4.5.1 Systemic Idiopathic Juvenile Arthritis Treatment Market Size and Y-o-Y Growth
4.5.2 Systemic Idiopathic Juvenile Arthritis Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Adalimumab Biosimilar
5.2.2 Canakinumab
5.2.3 Golimumab
5.2.4 Tocilizumab Biosimilar
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Systemic Idiopathic Juvenile Arthritis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Systemic Idiopathic Juvenile Arthritis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Adalimumab Biosimilar
9.6.2 Canakinumab
9.6.3 Golimumab
9.6.4 Tocilizumab Biosimilar
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Adalimumab Biosimilar
10.6.2 Canakinumab
10.6.3 Golimumab
10.6.4 Tocilizumab Biosimilar
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Adalimumab Biosimilar
11.6.2 Canakinumab
11.6.3 Golimumab
11.6.4 Tocilizumab Biosimilar
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Adalimumab Biosimilar
12.6.2 Canakinumab
12.6.3 Golimumab
12.6.4 Tocilizumab Biosimilar
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Adalimumab Biosimilar
13.6.2 Canakinumab
13.6.3 Golimumab
13.6.4 Tocilizumab Biosimilar
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Systemic Idiopathic Juvenile Arthritis Treatment Market: Competitive Dashboard
14.2 Global Systemic Idiopathic Juvenile Arthritis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alteogen Inc.
14.3.2 Bristol-Myers Squibb Company
14.3.3 Epirus Biopharmaceuticals, Inc.
14.3.4 Johnson & Johnson
14.3.5 Momenta Pharmaceuticals, Inc.
14.3.6 Mycenax Biotech Inc.
14.3.7 Novartis AG
14.3.8 Oncobiologics, Inc.
